G. Nahler

发表

carry-over effect

G. Nahler, 2009 .

standardized response mean (SRM)

G. Nahler, 2009 .

: Accelerated testing

G. Nahler, R. Ripeanu, A. Portoacă, 1999 .

repeated measures design

G. Nahler, 2009 .

anatomical therapeutic chemical classification system (ATC)

G. Nahler, 2009 .

dose escalation study

G. Nahler, 2009 .

Committee for Proprietary Medicinal Products (CPMP)

Gerhard Nahler, G. Nahler, 2009 .

Cannabidiol and Contributions of Major Hemp Phytocompounds to the “Entourage Effect”; Possible Mechanisms

G. Nahler, 2019, Alternative, Complementary & Integrative Medicine.

Pure Cannabidiol versus Cannabidiol-Containing Extracts: Distinctly Different Multi-Target Modulators

G. Nahler, Trevor M. Jones, 2018, Alternative, Complementary & Integrative Medicine.

disease free survival (DFS)

G. Nahler, 2009 .

correction of errors

G. Nahler, 2009 .

Pearson Correlation Coefficient

Gerhard Nahler, G. Nahler, 2020, Definitions.

Dictionary of Pharmaceutical Medicine

G. Nahler, 2013, Springer Vienna.

Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics

G. Nahler, 2022, Pharmaceutical Medicine.

Cannabidiol Possibly Improves Survival of Patients with Pancreatic Cancer: A Case Series

G. Nahler, R. Likar, 2020 .

quality-adjusted life-years (QALY)

G. Nahler, 2009 .

over-the-counter (OTC)

G. Nahler, 2009 .

Glomerular filtration rate (GFR)

G. Nahler, 2020, Definitions.

randomized controlled clinical trial

G. Nahler, 2009 .

accelerated approval program

G. Nahler, 2009 .

first-pass effect

G. Nahler, 2009 .

cost/effectiveness analysis (CEA)

G. Nahler, 2009 .

Cannabidiol – A Role for COVID-19?

G. Nahler, 2020, Online Journal of Complementary & Alternative Medicine.

long-term use

G. Nahler, 2009 .

Amoxycillin in Bronchitis. Comparison of Two versus Three Daily Doses

G. Nahler, R. Muhr, A. Fassl, 1987, The Journal of international medical research.

minimal clinically important difference (MCID)

G. Nahler, 2009 .

post-authorisation safety study (PASS)

G. Nahler, 2009 .

Committee for Veterinary Medicinal Products (CVMP)

G. Nahler, 2009 .

The use of cannabis in supportive care and treatment of brain tumor.

G. Nahler, R. Likar, 2017, Neuro-oncology practice.

investigational device exemption (IDE)

G. Nahler, 2009 .

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans

G. Nahler, A. Zuardi, F. Grotenhermen, 2017, Cannabis and cannabinoid research.

multi-investigator study

G. Nahler, 2009 .

In vitro Translation of R-factor DNA

G. Nahler, G. Högenauer, 1977 .

The Austrian Immunoglobulin in MS (AIMS) Study: Final Analysis

G. Nahler, F. Fazekas, B. Mamoli, 2000, Multiple sclerosis.

The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians

G. Nahler, R. Likar, Trevor M. Jones, 2021, Journal of Neuroimmune Pharmacology.

Could cannabidiol play a role in the treatment of chronic pain

G. Nahler, 2018 .

dose response relationship

G. Nahler, 2009 .

Dear Doctor letter

G. Nahler, 2009 .

G. Nahler, Trevor M. Jones, Eberhard Pirich, 2020 .

European Public Assessment Report (EPAR)

G. Nahler, 2009 .

defined daily dose (DDD)

G. Nahler, 2009 .

mean arterial blood pressure (MAP)

G. Nahler, 2009 .

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.

G. Nahler, F. Fazekas, B. Mamoli, 1997, Lancet.

Experimental Studies and First Retrospective Clinical Data Suggest a Possible Benefit of CBD in COVID-19

G. Nahler, R. Likar, Stefan Neuwersch-Sommeregger, 2021, Journal of Pharmacology & Pharmaceutical Research.

health care expenditure

G. Nahler, 2009 .

intent-to-treat analysis

G. Nahler, 2009 .

summary of product characteristics (SPC, SmPC)

G. Nahler, 2009 .

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

G. Nahler, F. Fazekas, B. Mamoli, 1997, Multiple sclerosis.

Escherichia coli heat-labile enterotoxin: DNA-directed in vitro synthesis and structure.

G. Nahler, F. Dorner, G. Högenauer, 1979, Proceedings of the National Academy of Sciences of the United States of America.

clinical trial report

G. Nahler, 2009 .

Decontamination of the Oral Cavity. Effect of Six Local Anti-Microbial Preparations in Comparison to Water and Parafilm as Controls

G. Nahler, C. Matula, M. Hildebrandt, 1988, The Journal of international medical research.

recommended daily allowances

G. Nahler, 2009 .

Route of Administration

G. Nahler, 2020, Definitions.

International Conference on Harmonisation (ICH)

Gerhard Nahler, G. Nahler, 2009 .

European Medicines Evaluation Agency (EMEA)

G. Nahler, 2009 .

investigational medicinal product dossier (IMPD)

G. Nahler, 2009 .

first-in-man study

Gerhard Nahler, G. Nahler, 2009 .

In vitro antibacterial activity of gramicidin and tyrothricin.

G. Nahler, G. Ruckdeschel, F. Beaufort, 1983, Arzneimittel-Forschung.

recommended dietary allowances (RDA)

G. Nahler, 2009 .

pharmaceutical quality assurance

G. Nahler, 2009 .

secondary attack rate

G. Nahler, 2009 .

medical device reporting (MDR)

Gerhard Nahler, G. Nahler, 2009 .

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

G. Nahler, 2017 .

Two-Tailed Test

Gerhard Nahler, G. Nahler, 2022, The SAGE Encyclopedia of Research Design.

North American Free Trade Agreement (NAFTA)

Gerhard Nahler, G. Nahler, 2009 .

data and safety monitoring board (DSMB)

G. Nahler, 2009 .

Salivary levels of gramicidin after use of a tyrothricin-containing gargle/mouth-wash and tyrothricin lozenges.

G. Nahler, F. Kreuzig, C. Matula, 1988, International journal of clinical pharmacology research.

type II error

G. Nahler, 2009 .

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis

G. Nahler, F. Fazekas, B. Mamoli, 1997, The Lancet.

Endometriosis – an indication for cannabinoids ?

G. Nahler, 2020, Traditional Medicine.

minimal inhibitory concentration (MIC)

G. Nahler, 2009 .

Correction of Errors

G. Nahler, 1962, Crop Science.

coefficient of variation (CV)

G. Nahler, 2009 .

Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature

G. Nahler, R. Likar, M. Stultschnig, 2019, AntiCancer Research.

first-order kinetics

G. Nahler, 2009 .

How safe are hemp-based food products? A review and risk assessment of analytical data from Germany

G. Nahler, F. Steinmetz, J. C. Wakefield, 2022, Nutrition & Food Science.

Karnofsky Performance Status

G. Nahler, 2020, Definitions.

standard deviation (SD)

Gerhard Nahler, G. Nahler, 2009 .

Gross Domestic Product (GDP)

Gerhard Nahler, G. Nahler, 2009 .

NOTIFICATION AND SUBMISSION OF CLINICAL TRIALS TO REGULATORS

G. Nahler, D. Brunier, 1999 .

ECOG Performance Status

G. Nahler, 2020, Definitions.

Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme.

G. Nahler, R. Likar, M. Koestenberger, 2021, Cancer diagnosis & prognosis.

Tumor Suppressor Gene

Médecine, G. Nahler, Yue Cheng, 2010 .

clinical trial manager

G. Nahler, 2009 .

New York Heart Association classification (NYHA)

G. Nahler, 2009 .

clinical trial compensation guidelines

G. Nahler, 2009 .

biological medicinal products

G. Nahler, 2009 .

International Federation of Pharmaceutical Manufacturers Association (IFPMA)

G. Nahler, 2009 .

[Cannabidiol in cancer treatment].

G. Nahler, R. Likar, M. Köstenberger, 2020, Schmerz.

health-related quality of life (HRQOL)

G. Nahler, 2009 .

visual analogue scale (VAS)

Gerhard Nahler, G. Nahler, 2009 .

Cannabidiol bei Tumorerkrankungen

G. Nahler, R. Likar, M. Köstenberger, 2020, Der Schmerz.

Intravenous Immunoglobulins in Multiple Sclerosis: Results of the Austrian Immunoglobulin in Multiple Sclerosis (AIMS) Trial

G. Nahler, F. Fazekas, B. Mamoli, 1999, Transfusion Medicine and Hemotherapy.

product specification file

Gerhard Nahler, G. Nahler, 2009 .

between-subject design

Gerhard Nahler, G. Nahler, 2009 .

GCP DEFICIENCIES IN CLINICAL TRIALS IN WESTERN AND EASTERN EUROPE : RESULTS OF INTERNATIONAL CLINICAL TRIAL CENTER AUDITS

G. Nahler, D. Brunier, 1998 .

Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa.

G. Nahler, A. Diem, M. Laimer, 2022, Indian journal of dermatology, venereology and leprology.

area under the curve (AUC)

Gerhard Nahler, G. Nahler, 2009 .

no-effect level

G. Nahler, 2009 .

direct medical costs

G. Nahler, 2009 .

Abbreviated New Drug Application

G. Nahler, 2020, Definitions.

long-term use

G. Nahler, 2009 .

Pharmaceutical expenditure

G. Nahler, 2018, Health at a Glance: Europe.

Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin.

G. Nahler, G. Müller, G. Gerstner, 1989, Gynecologic and Obstetric Investigation.

Replication Study

G. Nahler, Toni E. Obermeyer, A. Streeter, 2017 .

Common Technical Document (CTD)

Gerhard Nahler, G. Nahler, 2009 .

What are the perspectives of cannabidiol (CBD) for the treatment of glioblastoma

G. Nahler, 2018 .

case-fatality rate

G. Nahler, 2009 .

number of observations

Gerhard Nahler, G. Nahler, 2009 .

AJCC Staging (= American Joint Committee of Cancer)

G. Nahler, 2009 .

PACKAGE INSERT

Hauptadministrator, Hauptadministrator, G. Nahler, 2004 .

Committee for Veterinary Medicinal Products (CVMP)

G. Nahler, 2009 .

cut-off date

G. Nahler, 2009 .

double-dummy technique

G. Nahler, 2009 .

Salivary levels of gramicidin after use of a tyrothricin lozenge and a tyrothricin gargle/mouth-wash.

G. Nahler, F. Kreuzig, 1983, International journal of clinical pharmacology research.

IFPMA code of pharmaceutical marketing practices

G. Nahler, 2009 .

Phase III

G. Nahler, 2019, Encyclopedic Dictionary of Archaeology.